SCHEMBL3253198

SCHEMBL3253198

CCOC(=O)c1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Nc4cccc(Cl)c4)cc3c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
LMNA P02545 5/20 0.49
TP53 P04637 3/20 0.49
THRB P10828 3/20 0.49
HIF1A Q16665 1/20 0.46
BRD4 O60885 1/20 0.46
ALOX15 P16050 2/20 0.45
POLB P06746 5/20 0.45
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 3/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALOX5 P09917 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
ESR1 P03372 1/20 0.43
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3247456 0.93 BRD4 (0.55) MAPTLMNATP53THRBHIF1A
SCHEMBL3254167 0.92 MAPT (0.51) MAPTLMNATP53THRBHIF1A
SCHEMBL3249958 0.91 MAPT (0.50) MAPTLMNATP53THRBALOX15
SCHEMBL3249007 0.91 HSD17B10 (0.51) MAPTLMNATP53THRBHIF1A
SCHEMBL3254789 0.91 PKM (0.51) MAPTLMNATP53THRBALOX15
SCHEMBL3250340 0.89 ALDH1A1 (0.55) MAPTLMNATP53THRBPOLB
SCHEMBL3254022 0.89 HIF1A (0.52) MAPTLMNATP53THRBHIF1A
SCHEMBL3252388 0.87 HSD17B10 (0.47) MAPTLMNATP53THRBALOX15
SCHEMBL3241955 0.87 MAPT (0.53) MAPTLMNATP53ALOX15POLB
SCHEMBL3251809 0.87 MAPT (0.44) MAPTLMNATP53THRBHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MAPT 734/4885LMNA 3096/4885TP53 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.